![Andrew Levin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Levin
Founder at
Imbria Pharmaceuticals, Inc.
Net worth: - $ as of 2026-05-30
Profile
Andrew D.
Levin is the founder of Imbria Pharmaceuticals, Inc., founded in 2018, serving as Director.
Dr. Levin was the founder of Climb Bio, Inc., founded in 2018, serving as Director from 2024 to 2026.
Dr. Levin currently serves as Director at Clear Creek Bio, Inc., Lusaris Therapeutics, Inc., and Superluminal Medicines, Inc. Dr. Levin is Partner & Managing Director at RA Capital Management LP (Private Equity) since 2015 and Partner at RA Capital Management LP since 2023.
Former positions include Director at Aktis Oncology, Inc., Clinton Group, Inc., Arvinas Operations, Inc., Synthorx, Inc. (Independent Director), Arvinas, Inc. (Independent Director), and Athenen Therapeutics, Inc. (President & Director).
Dr. Levin was Director-Pharmaceutical Sciences at Clinton Health Access Initiative from 2010 to 2012.
Dr. Levin was Independent Director at Vor Biopharma, Inc. from 2025 to 2026.
Other former roles include Manager at Genzyme Corp., Analyst at Tang Capital Management LLC, Analyst at Citadel Advisors LLC from 2009 to 2010, Principal at H.I.G Capital LLC (Private Equity), Principal at H.I.G.
BioHealth Partners LLC, and Vice President at H.I.G.
BioVentures Advisors LLC from 2012 to 2015.
Dr. Levin earned a doctorate from Massachusetts Institute of Technology in 2005, an undergraduate degree from Princeton University in 1999, and a doctorate from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CLIMB BIO, INC. -.--% | 2026-06-04 | 0 ( -.--% ) | - $ | 2026-05-30 |
VOR BIOPHARMA, INC. -.--% | 2026-06-10 | 0 ( -.--% ) | - $ | 2026-05-30 |
Andrew Levin active positions
| Companies | Position | Start |
|---|---|---|
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Portfolio Manager-Equities | 2014-12-31 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Investor | 2014-12-31 |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Director/Board Member | - |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Founder | 2017-12-31 |
Lusaris Therapeutics, Inc.
 Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders | Director/Board Member | - |
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Operates as a generative biological and chemical company | Director/Board Member | - |
Former positions of Andrew Levin
| Companies | Position | End |
|---|---|---|
| VOR BIOPHARMA INC. | Director/Board Member | 2026-07-05 |
| CLIMB BIO, INC. | Chief Executive Officer | 2020-09-30 |
| SYNTHORX, INC. | Director/Board Member | 2018-04-30 |
| ░░░░░░ ░░░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Andrew Levin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
97
1st degree connections
24
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 24 |
|---|---|
Clinton Group, Inc.
 Clinton Group, Inc. Investment ManagersFinance Clinton Group seeks to achieve consistent returns with low volatility in all of their funds through a highly systematic relative value approach that attempts to meet clients' return objectives without market forecasting or speculation. The firm employs state-of-the-art technology, quantitative analysis, market information and market experience to evaluate potential investment opportunities. They seek to hedge the component risks in securities to extract a stable and secure return. Clinton Group is an activist firm and is included in the SharkWatch50 as one the 50 most prominent activist investors. | Finance |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Tang Capital Management LLC
 Tang Capital Management LLC Investment ManagersFinance Tang Capital focuses on investments in small-cap US companies in the life sciences sector. | Finance |
Citadel Advisors LLC
 Citadel Advisors LLC Investment ManagersFinance Citadel Advisors employs, for the benefit of the funds, proprietary investment strategies based upon fundamental research as well as on quantitative analysis. The firm invests in the global public equity, fixed-income, credit and options markets. | Finance |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Health Technology |
H.I.G Capital LLC (Private Equity)
 H.I.G Capital LLC (Private Equity) Investment ManagersFinance H.I.G Capital invests in mid-market companies located in the United States, Latin America, Europe and Middle East with an enterprise value of USD 50 - 1000 million. The firm targets companies operating in the fields of healthcare, technology and manufacturing sectors. It provides financing for acquisitions, corporate divestitures, MBOs, industry consolidations, recapitalizations, turnarounds, public to private and growth stage capital requirements. The firm acquires controlling and minority interests. | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
H.I.G. BioHealth Partners LLC
 H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners invests in companies located in the United States. The firm targets companies operating in the field of medical devices, biopharmaceuticals, digital health, tool & diagnostics and product related services. It provides financing for acquisition, IPO and growth stage capital requirements in the form of equity and debt. It also makes follow on investments. | Finance |
H.I.G. BioVentures Advisors LLC | |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Commercial Services |
Synthorx, Inc.
 Synthorx, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that uses synthetic biology to discover and develop protein therapeutics | Health Technology |
Arvinas, Inc.
 Arvinas, Inc. BiotechnologyHealth Technology Engages in discovery, development and commercialization of therapies to degrade disease-causing proteins | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Athenen Therapeutics, Inc.
 Athenen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders | Health Technology |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Operates as a generative biological and chemical company | Health Technology |
- Stock Market
- Insiders
- Andrew Levin
Choose MarketScreener 
